0IFR Stock Overview Designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ekso Bionics Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ekso Bionics Holdings Historical stock prices Current Share Price US$0.64 52 Week High US$3.10 52 Week Low US$0.60 Beta 1.46 1 Month Change -10.99% 3 Month Change -48.38% 1 Year Change -59.41% 3 Year Change -78.41% 5 Year Change n/a Change since IPO -97.36%
Recent News & Updates
Ekso Bionics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Dec 14
Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.24 loss in 3Q 2023) Oct 29
Ekso Bionics Holdings, Inc. to Report Q3, 2024 Results on Oct 28, 2024 Oct 21
New major risk - Shareholder dilution Sep 01 Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million. Aug 31
Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million. Aug 30
See more updates
Ekso Bionics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement Dec 14
Third quarter 2024 earnings released: US$0.10 loss per share (vs US$0.24 loss in 3Q 2023) Oct 29
Ekso Bionics Holdings, Inc. to Report Q3, 2024 Results on Oct 28, 2024 Oct 21
New major risk - Shareholder dilution Sep 01 Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $5.9971 million. Aug 31
Ekso Bionics Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million. Aug 30
New major risk - Financial position Aug 29
Forecast to breakeven in 2026 Jul 31
Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.31 loss in 2Q 2023) Jul 30 Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million. Jul 30
Ekso Bionics Holdings, Inc. to Report Q2, 2024 Results on Jul 29, 2024 Jul 22
Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors Jun 18
First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.33 loss in 1Q 2023) May 01
Forecast to breakeven in 2026 May 01
Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024 Apr 28
Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Apr 23
No longer forecast to breakeven Mar 06
Full year 2023 earnings released: US$1.10 loss per share (vs US$1.16 loss in FY 2022) Mar 05
Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024 Feb 27
Forecast to breakeven in 2026 Jan 23 Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million. Jan 18
Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million. Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.
Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR Jan 09
Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 Jan 05
Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal Dec 12
Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.33 loss in 3Q 2022) Oct 29
Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Oct 20 Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq Oct 01
New major risk - Financial position Jul 30
Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.23 loss in 2Q 2022) Jul 29
Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023 Jul 23
High number of new and inexperienced directors Jun 06
Executive Chairman of the Board recently sold US$66k worth of stock May 29
High number of new and inexperienced directors May 18
High number of new and inexperienced directors May 04
No longer forecast to breakeven Apr 03
Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021) Mar 31
Forecast to breakeven in 2025 Jan 12
Ekso Bionics Holdings, Inc Announces Director Changes Dec 10 Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million. Dec 06
Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer
Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.10 loss in 2Q 2021) Aug 03
Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 22
Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients Jun 14
Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes May 27
Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022 May 02
Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022 Feb 18
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020) Nov 04
Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020) Jul 31
First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020) May 03
Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019) Feb 27
Revenue misses expectations Feb 27
Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021 Feb 27
Ekso Bionics Holdings, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Ekso Bionics Holdings, Inc. Announces Resignation of Ted Wang as Member of the Board of Director Feb 09 Shareholder Returns 0IFR GB Medical Equipment GB Market 7D 6.5% -2.3% -2.2% 1Y -59.4% -10.6% 2.4%
See full shareholder returns
Return vs Market: 0IFR underperformed the UK Market which returned 2.4% over the past year.
Price Volatility Is 0IFR's price volatile compared to industry and market? 0IFR volatility 0IFR Average Weekly Movement 13.2% Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0IFR's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0IFR's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of UK stocks.
About the Company Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Show more Ekso Bionics Holdings, Inc. Fundamentals Summary How do Ekso Bionics Holdings's earnings and revenue compare to its market cap? 0IFR fundamental statistics Market cap US$12.76m Earnings (TTM ) -US$11.13m Revenue (TTM ) US$17.68m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0IFR income statement (TTM ) Revenue US$17.68m Cost of Revenue US$8.52m Gross Profit US$9.17m Other Expenses US$20.30m Earnings -US$11.13m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.51 Gross Margin 51.84% Net Profit Margin -62.95% Debt/Equity Ratio 36.0%
How did 0IFR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 08:07 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ekso Bionics Holdings, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Gregory Chodaczek B. Riley Securities, Inc. Craig Bijou Cantor Fitzgerald & Co. Gregory Chodaczek CRT Capital Group
Show 8 more analysts 